| (84) |
Designated Contracting States: |
|
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL
NO PL PT RO RS SE SI SK SM TR |
|
Designated Extension States: |
|
BA ME |
|
Designated Validation States: |
|
MA MD |
| (30) |
Priority: |
02.11.2015 US 201562249836 P
11.08.2016 US 201662373654 P
|
| (43) |
Date of publication of application: |
|
12.09.2018 Bulletin 2018/37 |
| (60) |
Divisional application: |
|
24200732.6 |
| (73) |
Proprietor: Five Prime Therapeutics, Inc. |
|
Thousand Oaks, CA 91320 (US) |
|
| (72) |
Inventors: |
|
- BRENNAN, Thomas
South San Francisco, California 94080 (US)
- BELLOVIN, David
South San Francisco, California 94080 (US)
- BUSHA, David
South San Francisco, California 94080 (US)
- SENNINO, Barbara
South San Francisco, California 94080 (US)
|
| (74) |
Representative: Dörries, Hans Ulrich |
|
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstrasse 16
80333 München
80333 München (DE) |
| (56) |
References cited: :
|
| |
|
|
- BORK K ET AL: "Increasing the sialylation of therapeutic glycoproteins: the potential
of the sialic acid biosynthetic pathway", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN
CHEMICAL SOCIETY AND AMERICAN PHARMACEUTICAL ASSOCIATION, US, vol. 98, no. 10, 1 October
2009 (2009-10-01), pages 3499 - 3508, XP002572996, ISSN: 0022-3549, [retrieved on
20090206], DOI: 10.1002/JPS.21684
- S. T. HAILE ET AL: "Soluble CD80 Restores T Cell Activation and Overcomes Tumor Cell
Programmed Death Ligand 1-Mediated Immune Suppression", THE JOURNAL OF IMMUNOLOGY,
vol. 191, no. 5, 5 August 2013 (2013-08-05), US, pages 2829 - 2836, XP055334763, ISSN:
0022-1767, DOI: 10.4049/jimmunol.1202777
- S. T. HAILE ET AL: "A Soluble Form of CD80 Enhances Antitumor Immunity by Neutralizing
Programmed Death Ligand-1 and Simultaneously Providing Costimulation", CANCER IMMUNOLOGY
RESEARCH, vol. 2, no. 7, 2 April 2014 (2014-04-02), US, pages 610 - 615, XP055334764,
ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-13-0204
- OSTRAND-ROSENBERG SUZANNE ET AL: "Novel strategies for inhibiting PD-1 pathway-mediated
immune suppression while simultaneously delivering activating signals to tumor-reactive
T cells", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN/HEIDELBERG, vol. 64,
no. 10, 20 March 2015 (2015-03-20), pages 1287 - 1293, XP035533178, ISSN: 0340-7004,
[retrieved on 20150320], DOI: 10.1007/S00262-015-1677-5
- DANIEL M. CZAJKOWSKY ET AL: "Fc-fusion proteins: new developments and future perspectives",
EMBO MOLECULAR MEDICINE, vol. 4, no. 10, 26 July 2012 (2012-07-26), pages 1015 - 1028,
XP055160259, ISSN: 1757-4676, DOI: 10.1002/emmm.201201379
- RICARDO J. SOLÁ ET AL: "Glycosylation of Therapeutic Proteins", BIODRUGS, vol. 24,
no. 1, 1 February 2010 (2010-02-01), pages 9 - 21, XP055016446, ISSN: 1173-8804, DOI:
10.2165/11530550-000000000-00000
|
|
